Patents Assigned to Merck Sharp & Dohme Corp.
-
Publication number: 20230242644Abstract: A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of each of a peptide set forth in SEQ ID NO: 1, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.Type: ApplicationFiled: February 14, 2023Publication date: August 3, 2023Applicants: BioLineRx Ltd., Merck Sharp & Dohme Corp.Inventors: Abi VAINSTEIN-HARAS, Ella SORANI, Irit GLIKO-KABIR, Osnat BOHANA-KASHTAN, Amnon PELED
-
Publication number: 20230192876Abstract: The present invention relates to methods of treating cancer by administering an anti-CD27 antibody as a monotherapy or as a part of a combination thereof.Type: ApplicationFiled: October 29, 2020Publication date: June 22, 2023Applicant: Merck Sharp & Dohme Corp.Inventors: Elliot K. Chartash, Amy M. Beebe, Jason K. Cheung, Konstantin Dobrenkov, Claire H. Li, Richard Wnek
-
Patent number: 11673877Abstract: The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib.Type: GrantFiled: June 4, 2021Date of Patent: June 13, 2023Assignees: Tesaro, Inc., Merck Sharp & Dohme Corp.Inventors: George Wu, John Chaber, Arlene E. McKeown, Jennifer R. Foley
-
Publication number: 20230167168Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.Type: ApplicationFiled: June 23, 2021Publication date: June 1, 2023Applicant: Merck Sharp & Dohme Corp.Inventors: Jeanne E. Baker, Sophie Parmentier Batteur, Ming-Tang Chen, Alan C. Cheng, Chung-Ming Hsieh, Carl Mieczkowski, Sokreine Suon
-
Patent number: 11649243Abstract: The application is directed to efficient and economical processes as described in more detail below for the preparation of the beta 3 agonists of the formula of I-7 and intermediate compounds that can be used for making these agonists. The present disclosure relates to a process for making beta-3 agonists and intermediates using ketoreductase (KRED) biocatalyst enzymes and methods of using the biocatalysts.Type: GrantFiled: August 11, 2021Date of Patent: May 16, 2023Assignee: Merck Sharp & Dohme Corp.Inventors: Feng Xu, Zhuqing Liu, Richard Desmond, Jeonghan Park, Alexei Kalinin, Birgit Kosjek, Hallena Strotman, Hongmei Li, Johannah Moncecchi
-
Publication number: 20230105982Abstract: Insulin-incretin conjugates comprising a peptide having agonist activity at the glucagon-like 1 (GLP-1) receptor, the glucagon (GCG) receptor, and/or the gastric inhibitory protein (GIP) receptor conjugated to an insulin molecule having agonist activity at the insulin receptor and use of the conjugates for treatment of metabolic diseases, for example, Type 2 diabetes, are described.Type: ApplicationFiled: July 28, 2021Publication date: April 6, 2023Applicant: Merck Sharp & Dohme Corp.Inventors: Anandan Palani, Chunhui Huang, Zhiqiang Yang, Lin Yan, Songnian Lin, Pei Huo, Qiaolin Deng, Elisabetta Bianchi, Federica Orvieto
-
Publication number: 20230054411Abstract: In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.Type: ApplicationFiled: November 26, 2019Publication date: February 23, 2023Applicant: Merck Sharp & Dohme Corp.Inventors: Yonglian Zhang, Amjad Ali, Jared Cumming, Duane DeMong, Qiaolin Deng, Thomas H. Graham, Elisabeth Hennessy, Matthew A. Larsen, Kun Liu, Ping Liu, Umar Faruk Mansoor, Jianping Pan, Christopher W. Plummer, Aaron Sather, Uma Swaminathan, Huijun Wang
-
Publication number: 20230023066Abstract: The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.Type: ApplicationFiled: October 20, 2020Publication date: January 26, 2023Applicant: Merck Sharp & Dohme Corp.Inventors: Mitchell H. Keylor, Michael J. Ardolino, Ryan W. Chau, Peter H. Fuller, Anmol Gulati, Rebecca Elizabeth Johnson, Solomon D. Kattar, Kaila A. Margrey, Gregori J. Morriello, Santhosh F. Neelamkavil, Xin Yan, Elsie C. Yu, Cayetana Carmela Zarate Saez
-
Publication number: 20230018413Abstract: The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: August 3, 2020Publication date: January 19, 2023Applicant: Merck Sharp & Dohme Corp.Inventors: Stephane L. Bogen, Ping Chen, Dane James Clausen, Jinsong Hao, Dipannita Kalyani, Michael T. Rudd, Shawn P. Walsh, Lan Wei, Dexi Yang
-
Publication number: 20230008022Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.Type: ApplicationFiled: November 25, 2019Publication date: January 12, 2023Applicant: Merck Sharp & Dohme Corp.Inventors: Dane Clausen, Ping Chen, Xavier Fradera, Liangqin Guo, Yongxin Han, Shuwen He, Xianhai Huang, Joseph Kozlowski, Guoqing Li, Theodore A. Martinot, Alexander Pasternak, Andreas Verras, Li Xiao, Feng Ye, Wensheng Yu, Rui Zhang
-
Patent number: 11545270Abstract: A dossier change control management system periodically ingests data regarding a regulated product from multiple data stores. The dossier change control management system updates dossier data describing a dossier history for the regulated product using the received data. The dossier includes multiple documents in a standardized format and is updated based on a data mapping indicating correspondence between fields of the documents and portions of the received data. An out-of-expectation scenario for the dossier is identified based on regulatory requirements and an alert generated. A report with information about the out-of-expectation scenario is provided for display at a client device based on the alert.Type: GrantFiled: January 21, 2020Date of Patent: January 3, 2023Assignee: Merck Sharp & Dohme Corp.Inventors: Christina Elizabeth Frey, Andrew Hakfan Chen, Christopher Michael Lee, Nirdosh Jagota
-
Publication number: 20220409724Abstract: The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof,—and the use of the combination therapies for the treatment of a cancer.Type: ApplicationFiled: October 28, 2020Publication date: December 29, 2022Applicants: Eisai R&D Management Co., Ltd., Merck Sharp & Dohme Corp., MSD International GmbHInventors: Yoichi OZAWA, Yasuhiro FUNAHASHI, Yu KATO
-
Publication number: 20220411507Abstract: Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti-PD-1 or anti-PD-L1 antibody, or antibody fragment thereof.Type: ApplicationFiled: March 10, 2020Publication date: December 29, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Drake LaFace, Juha Punnonen, Edward Bowman, David Bauche, Alissa Chackerian, Jeffery Grein, Smita Mauze, Anandi Sawant, Lakshmanan Annamalai
-
Publication number: 20220396571Abstract: The present disclosure relates to compounds of formula (I) that are useful as modulators of ?7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation.Type: ApplicationFiled: October 29, 2020Publication date: December 15, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Ian M. Bell, Brendan M. Crowley, Phillippe Nantermet
-
Publication number: 20220397570Abstract: An ultraviolet (UV) absorbance assay for measuring the concentration of large RNA molecules such as mRNA in suspensions comprising RNA-lipid nanoparticles (RNA-LNPs) is described.Type: ApplicationFiled: September 22, 2020Publication date: December 15, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Lee J. Klein, Leia C. Epstein
-
Publication number: 20220380854Abstract: The invention relates to (i) an angiogenesis gene signature and (ii) a monocytic myeloid-derived suppressor cell (mMDSC) gene signature that are each predictive of patient response to treatment with a PD-1 antagonist, wherein the angiogenesis signature comprises five or more genes. More specifically, a lower angiogenesis score is associated with favorable response to a PD-1 antagonist in a patient with cancer. Similarly, a lower mMDSC score is associated with favorable response to a PD-1 antagonist in a patient with cancer. Also provided are methods of treating a cancer patient with a PD-1 antagonist that were identified as either (i) positive for the angiogenesis gene signature biomarker of the invention or (ii) positive for the mMDSC gene signature biomarker of the invention.Type: ApplicationFiled: October 29, 2020Publication date: December 1, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Mark D. Ayers, Razvan Cristescu, Andrey Loboda, Jared K. Lunceford, Hua Ma, Terrill K. McClanahan, Michael Nebozhyn, Chunsheng Zhang
-
Publication number: 20220380469Abstract: The present invention relates to methods for treating metastatic triple negative breast cancer in a human patient which has been identified as having a PD-L1 enriched tumor comprising administering, as monotherapy, an anti-PD-1 antibody or antigen binding fragment thereof (e.g., pembrolizumab) in specific amounts to the patient about every three or six weeks, wherein the PD-L1 enriched tumor is a tumor identified as having a CPS score of ?10.Type: ApplicationFiled: September 23, 2020Publication date: December 1, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Gursel Aktan, Roger Delemere Dansey, Vassiliki Karantza, Zifang Guo, Jaime A. Mejia, Shu-Chih Su, Jing Zhao, Xuan Zhou
-
Publication number: 20220363656Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are antagonists of leukotriene B4 receptor 1 (BLT1) and may be useful in the treatment, prevention and suppression of diseases mediated by the leukotriene B4 receptor 1 (BLT1). The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, insulin resistance, hyperglycemia, dyslipidemia, lipid disorders, obesity, hypertension, Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, metabolic syndrome, atherosclerosis, and cancer.Type: ApplicationFiled: June 10, 2021Publication date: November 17, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Yongxin Han, Jongwon Lim, Satyanarayana Tummanapalli, Phieng Siliphaivanh, Kerrie Spencer
-
Publication number: 20220363707Abstract: The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.Type: ApplicationFiled: August 5, 2019Publication date: November 17, 2022Applicants: Merck Sharp & Dohme Corp., MSD International GmbHInventors: Michelle Machacek, David Witter, Craig Gibeau, Chunhui Huang, Shuhei Kawamura, David L. Sloman, Phieng Siliphaivanh, Ryan Quiroz, Murray Wan, Sebastian Schneider, Charles S. Yeung, Michael H. Reutershan, Timothy J. Henderson, Jean-Laurent Paparin, Houcine Rahali, Jonathan M. E. Hughes, Sulagna Sanyal, Yingchun Ye, David A. Candito, Patrick S. Fier, Steven M. Silverman
-
Publication number: 20220362277Abstract: This invention relates to novel implant drug delivery systems for long-acting delivery of antiviral drugs. These compositions are useful for the treatment or prevention of human immunodeficiency virus (HIV) infection.Type: ApplicationFiled: August 11, 2020Publication date: November 17, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Seth P. Forster, Stephanie Elizabeth Barrett, Ryan S. Teller, Morgan B. Giles, Athanas Koynov